WO1999006587A3 - Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex - Google Patents

Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex Download PDF

Info

Publication number
WO1999006587A3
WO1999006587A3 PCT/EP1998/004836 EP9804836W WO9906587A3 WO 1999006587 A3 WO1999006587 A3 WO 1999006587A3 EP 9804836 W EP9804836 W EP 9804836W WO 9906587 A3 WO9906587 A3 WO 9906587A3
Authority
WO
WIPO (PCT)
Prior art keywords
identification
nucleic acid
acid sequences
multimeric
poly
Prior art date
Application number
PCT/EP1998/004836
Other languages
French (fr)
Other versions
WO1999006587A2 (en
Inventor
Fritz Rudert
Liming Ge
Vic Ilag
Original Assignee
Morphosys Ag
Fritz Rudert
Liming Ge
Vic Ilag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag, Fritz Rudert, Liming Ge, Vic Ilag filed Critical Morphosys Ag
Priority to JP2000505327A priority Critical patent/JP2002501721A/en
Priority to CA002297070A priority patent/CA2297070A1/en
Priority to EP98946272A priority patent/EP1005569A2/en
Publication of WO1999006587A2 publication Critical patent/WO1999006587A2/en
Publication of WO1999006587A3 publication Critical patent/WO1999006587A3/en
Priority to US09/495,880 priority patent/US6667150B1/en
Priority to US10/634,862 priority patent/US7049135B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to methods for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex by screening for polyphage particles. Furthermore, the invention relates to products and uses thereof for the identification of nucleic acid sequences in accordance with the present invention.
PCT/EP1998/004836 1997-08-01 1998-08-03 Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex WO1999006587A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000505327A JP2002501721A (en) 1997-08-01 1998-08-03 Novel method and phage for identifying nucleic acid sequences encoding members of multimeric (poly) peptide complexes
CA002297070A CA2297070A1 (en) 1997-08-01 1998-08-03 Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
EP98946272A EP1005569A2 (en) 1997-08-01 1998-08-03 Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
US09/495,880 US6667150B1 (en) 1997-08-01 2000-02-01 Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly) peptide complex
US10/634,862 US7049135B2 (en) 1997-08-01 2003-08-06 Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97113319.4 1997-08-01
EP97113319 1997-08-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/495,880 Continuation US6667150B1 (en) 1997-08-01 2000-02-01 Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly) peptide complex
US09495880 Continuation 2001-02-01

Publications (2)

Publication Number Publication Date
WO1999006587A2 WO1999006587A2 (en) 1999-02-11
WO1999006587A3 true WO1999006587A3 (en) 1999-07-01

Family

ID=8227163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/004836 WO1999006587A2 (en) 1997-08-01 1998-08-03 Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex

Country Status (5)

Country Link
US (2) US6667150B1 (en)
EP (1) EP1005569A2 (en)
JP (1) JP2002501721A (en)
CA (1) CA2297070A1 (en)
WO (1) WO1999006587A2 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0866805A1 (en) 1995-12-12 1998-09-30 Karolinska Innovations AB PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
EP1032660B1 (en) * 1997-11-17 2009-11-04 Micromet AG Method of identifying binding site domains that retain the capacity of binding to an epitop
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
ATE417925T1 (en) * 1999-07-20 2009-01-15 Morphosys Ag METHOD FOR PRESENTATION OF (POLY)PEPTIDES/PROTEINS ON BACTERIOPHAGE PARTICLES VIA DISULFIDE BINDINGS
KR20020093029A (en) 2000-04-11 2002-12-12 제넨테크, 인크. Multivalent Antibodies And Uses Therefor
ATE415978T1 (en) 2000-07-27 2008-12-15 Genentech Inc SEQUENTIAL ADMINISTRATION OF CPT-11 AND APO-2L POLYPEPTIDE
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
KR100810527B1 (en) 2001-01-15 2008-03-10 한국생명공학연구원 Method for Surface Display of Proteins on Genetic Carriers
US20030082630A1 (en) * 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
MY142238A (en) * 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP4753578B2 (en) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド Synthetic antibody phage library
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2004103272A2 (en) 2003-05-20 2004-12-02 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060030003A1 (en) * 2004-05-12 2006-02-09 Simon Michael R Composition and method for introduction of RNA interference sequences into targeted cells and tissues
US20050260214A1 (en) * 2004-05-12 2005-11-24 Simon Michael R Composition and method for introduction of RNA interference sequences into targeted cells and tissues
US20050255120A1 (en) * 2004-05-12 2005-11-17 Simon Michael R Composition and method for introduction of DNA directed RNA interference sequences into targeted cells and tissues
US20060068421A1 (en) * 2004-08-05 2006-03-30 Biosite, Inc. Compositions and methods for phage display of polypeptides
JP2008523815A (en) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド Humanized amyloid beta antibody for use in improving cognition
EP2468304A3 (en) 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
SI1928503T1 (en) 2005-08-24 2012-11-30 Immunogen Inc Process for preparing maytansinoid antibody conjugates
DOP2006000277A (en) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp ANTI MN ANTIBODIES AND METHODS FOR USE
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
CA2648718A1 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CA2671264C (en) 2006-11-30 2015-11-24 Research Development Foundation Improved immunoglobulin libraries
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
AU2008247819B2 (en) * 2007-05-01 2013-02-14 Research Development Foundation Immunoglobulin Fc libraries
UA100692C2 (en) 2007-05-02 2013-01-25 Мериал Лимитед Dna-plasmids having increased expression and stability
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
EP2190987B1 (en) * 2007-08-21 2012-11-14 MorphoSys AG Methods for the formation of disulphide bonds
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US8703921B2 (en) 2008-04-15 2014-04-22 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for delivering inhibitory oligonucleotides
US10485879B2 (en) 2008-04-15 2019-11-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
KR101764081B1 (en) 2008-04-30 2017-08-01 이뮤노젠 아이엔씨 Cross-linkers and their uses
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX2011008328A (en) 2009-02-05 2011-11-04 Immunogen Inc Novel benzodiazepine derivatives.
AR076284A1 (en) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag IMMUNOCONJUGADOS OF ANTIMESOTELINA AND USES OF THE SAME
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
TR201907573T4 (en) 2009-06-03 2019-06-21 Immunogen Inc CONJUGATION METHODS
WO2011008517A2 (en) * 2009-06-30 2011-01-20 Research Development Foundation Immunoglobulin fc polypeptides
RU2573915C2 (en) 2009-09-16 2016-01-27 Дженентек, Инк. Protein complexes containing superhelix and/or banding, and their use
IN2012DN02780A (en) 2009-10-06 2015-09-18 Immunogen Inc
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
EP2635674A4 (en) 2010-11-05 2014-11-05 Transbio Ltd Markers of endothelial progenitor cells and uses thereof
WO2012066129A1 (en) 2010-11-19 2012-05-24 Morphosys Ag A collection and methods for its use
CA2817448C (en) 2010-12-23 2019-01-22 F. Hoffmann-La Roche Ag Binding agent
CA2817455C (en) 2010-12-23 2019-04-16 F. Hoffmann-La Roche Ag Detection of a polypeptide dimer by a bivalent binding agent
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
WO2012085064A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
CA2826467C (en) 2011-02-07 2019-11-12 Research Development Foundation Engineered immunoglobulin fc polypeptides
DK2675479T3 (en) 2011-02-15 2016-04-11 Immunogen Inc cytotoxic benzodiazepine
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
KR20220009505A (en) 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 Preparation of maytansinoid antibody conjugates by a one-step process
JP6209159B2 (en) 2011-06-21 2017-10-04 イミュノジェン・インコーポレーテッド Novel maytansinoid derivatives having peptide linkers and conjugates thereof
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
MX2014009565A (en) 2012-02-10 2014-11-10 Genentech Inc Single-chain antibodies and other heteromultimers.
MX354862B (en) 2012-06-27 2018-03-23 Hoffmann La Roche Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof.
MX2014014065A (en) 2012-06-27 2015-02-04 Hoffmann La Roche Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof.
MX2014014804A (en) 2012-06-27 2015-02-12 Hoffmann La Roche Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof.
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
US10035817B2 (en) 2012-10-04 2018-07-31 Immunogen, Inc. Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane
US9901647B2 (en) 2013-02-28 2018-02-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9999680B2 (en) 2013-02-28 2018-06-19 Immunogen, Inc. Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN104341504B (en) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 Bispecific antibody
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
SG11201701455SA (en) 2014-09-03 2017-03-30 Immunogen Inc Cytotoxic benzodiazepine derivatives
MA40934A (en) 2014-11-19 2017-09-27 Immunogen Inc PROCESS FOR PREPARATION OF CELL BONDING AGENT-CYTOTOXIC AGENT CONJUGATES
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
EP3256490A1 (en) 2015-02-09 2017-12-20 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
KR20180105233A (en) 2016-02-05 2018-09-27 이뮤노젠 아이엔씨 Efficient methods for preparing cell-binder-cytotoxic agent conjugates
AU2018229277A1 (en) 2017-02-28 2019-10-10 Immunogen, Inc. Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
CN107446050A (en) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 The compound and method of Trop2 positive diseases treatment
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019818A1 (en) * 1990-06-20 1991-12-26 Affymax Technologies N.V. Peptide library and screening systems
WO1992020791A1 (en) * 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993019172A1 (en) * 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1997032017A1 (en) * 1996-02-26 1997-09-04 Morphosys Gesellschaft Für Proteinoptimierung Mbh Novel method for the identification of nucleic acid sequences encoding two or more interacting (poly)peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3852304T3 (en) 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organism as carrier for "Single Chain Antibody Domain (SCAD)".
DE68927933T2 (en) 1988-09-02 1997-08-14 Dyax Corp PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING POINTS
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
DE614989T1 (en) * 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Method for in vivo selection of ligand binding proteins.
FR2715940B1 (en) 1994-02-10 1996-04-26 Pasteur Merieux Serums Vacc Process for the preparation of a multi-combinatorial library of expression vectors of antibody genes, library and expression systems of "colonic" antibodies obtained.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019818A1 (en) * 1990-06-20 1991-12-26 Affymax Technologies N.V. Peptide library and screening systems
WO1992020791A1 (en) * 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993019172A1 (en) * 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1997032017A1 (en) * 1996-02-26 1997-09-04 Morphosys Gesellschaft Für Proteinoptimierung Mbh Novel method for the identification of nucleic acid sequences encoding two or more interacting (poly)peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUDERT, FRITZ ET AL: "A phage-based system to select multiple protein-protein interactions simultaneously from combinatorial libraries", FEBS LETT. (1998), 440(1,2), 135-140 CODEN: FEBLAL;ISSN: 0014-5793, XP002100835 *

Also Published As

Publication number Publication date
US20040048383A1 (en) 2004-03-11
EP1005569A2 (en) 2000-06-07
US6667150B1 (en) 2003-12-23
WO1999006587A2 (en) 1999-02-11
CA2297070A1 (en) 1999-02-11
US7049135B2 (en) 2006-05-23
JP2002501721A (en) 2002-01-22

Similar Documents

Publication Publication Date Title
WO1999006587A3 (en) Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
ZA988392B (en) Tie ligand homologues.
WO1999015653A3 (en) Tie ligand homologues
WO2000006738A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE)
EP0258411A4 (en) Dna encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof.
IL134537A0 (en) Nucleic acid encoding an april ligand or a fragment thereof, vectors and host cells containing the same and methods for the production thereof
WO2001075067A3 (en) Novel nucleic acids and polypeptides
WO2003052055A3 (en) Egvii endoglucanase and nucleic acids encoding the same
WO2001088088A3 (en) Novel nucleic acids and polypeptides
EP0832973A3 (en) GTP-binding protein
HU9601448D0 (en) Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
WO1993018146A3 (en) Proteins forming complexes with chaperones and ligands thereof, fragments thereof, preparation thereof and biological uses thereof
WO1997043409A3 (en) Method of providing novel dna sequences
EP0913476A3 (en) Ornithine carbamoyl transferase sequence and uses thereof
EP1047773A4 (en) Cubilin protein, dna sequences encoding cubilin and uses thereof
EP0832978A3 (en) Novel 3-dehydroquinate synthase
AUPP627498A0 (en) Novel peptides - i
EP0677115A4 (en) Tia-1 binding proteins and isolated complementary dna encoding the same.
AU3670395A (en) Hippocampus-associated proteins, dna sequences coding therefor and uses thereof
WO1997020928A1 (en) Novel semaphorin z and gene encoding the same
EP0897011A3 (en) Novel arginine deiminase
WO2001053453A3 (en) Novel bone marrow nucleic acids and polypeptides
AU1137699A (en) Novel reovirus-derived proteins, nucleic acids encoding same, and uses therefor
CA2194032A1 (en) Fused dna sequence, fused protein expressed from said fused dna sequence and method for expressing said fused protein
AU5882998A (en) Nucleic acid sequences encoding citrate transporter proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2297070

Country of ref document: CA

Ref country code: CA

Ref document number: 2297070

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998946272

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09495880

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998946272

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998946272

Country of ref document: EP